ALFA FinderBSE filing, NSE: GLENMARK. Summary written from the filing by ALFA Finder's alert engine.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,659.50
- Market cap
- ₹75,058 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 51.7×Sector 43.8×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 21.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Earnings Call Transcript: Key Takeaways
Like-for-like growth ~20% and ex-IGI EBITDA margin 21%, yet H1 operating cash was negative; H2 cash recovery is the test.
Glenmark Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue Rs 42,473 Mn, down 29.8% YoY on a reported basis. EBITDA Rs 8,638 Mn (20.3% margin); Adj PAT Rs 4,852 Mn (11.4% margin). North America headline is flattered by ISB 2001 licensing income.
Glenmark Pharmaceuticals Results Update
Glenmark Pharmaceuticals released its Q2 FY27 press release and MD&A for the quarter ended September 2026. Highlights show India growth and lower North America revenue.
Glenmark Pharmaceuticals Q2 FY27 Results: Net Profit ₹263.8 Cr, Down 56.8% YoY
Glenmark Pharmaceuticals Ltd reported revenue from operations of ₹4,247 Cr (-29.8% YoY) and net profit of ₹263.8 Cr (-56.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹263.8 Cr · -56.8% YoY
Glenmark Pharmaceuticals Other Announcement
Glenmark's partner IGI will present updated Phase 1 clinical data for ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma at the 68th ASH Annual Meeting. The presentation is scheduled for December 12, 2026.
Glenmark Pharmaceuticals Board Meeting Date
Glenmark Pharmaceuticals notified BSE of a board meeting on 05 Nov 2026 to consider unaudited Q2 FY27 results. No financial figures are disclosed in this advance intimation.
Other management change announcements
All →LGT Global Hospitality Management Change
LGT Global Hospitality's Company Secretary Ms. Ankita Jain resigned effective 15 Nov 2026. Ms. Dharshini S was appointed to the role w.e.f. 16 Nov 2026.
Edelweiss Financial Services Management Change
Promoter director Venkatachalam Ramaswamy resigned as Non-Executive Director and Vice Chairman effective November 11, 2026. He also sought reclassification from promoter to public category, pending approvals.
Abans Financial Services Management Change
Abans Financial Services' Chief Executive Officer Chintan Mehta resigned with immediate effect. Mayank Mundhra was appointed Whole-Time Director from November 11, 2026, subject to shareholder approval.
Ortin Global Management Change
Ortin Global's auditor M/s. Mathesh & Ramana resigned effective 12 Nov 2026, citing other professional commitments. S. D. Mehta and Co. was appointed as replacement.
Tierra Agrotech Management Change
Tierra Agrotech appointed Sridevi Dasari as Executive Director for 60 months, effective 16 November 2026. She is Group Company Secretary and Legal Head of CCL Products (India).
- Execution
- 60 months
National Peroxide Management Change
National Peroxide Limited appointed Mr. Amit Shah as General Manager – Sales & Marketing, effective 11 November 2026, as a senior management personnel change. The appointment was approved at a board meeting held the same day.